Terms: = Gastric cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
67 results:
1. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.
Hou Y; Li X; Yang Y; Shi H; Wang S; Gao M
Front Immunol; 2023; 14():1274431. PubMed ID: 38022654
[TBL] [Abstract] [Full Text] [Related]
2. System biology analysis to develop diagnostic biomarkers, monitoring pathological indexes, and novel therapeutic approaches for immune targeting based on maggot bioactive compounds and polyphenolic cocktails in mice with gastric cancer.
Kaviani E; Hajibabaie F; Abedpoor N; Safavi K; Ahmadi Z; Karimy A
Environ Res; 2023 Dec; 238(Pt 2):117168. PubMed ID: 37742751
[TBL] [Abstract] [Full Text] [Related]
3. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
4. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
Lordick F; Thuss-Patience P; Bitzer M; Maurus D; Sahin U; Türeci Ö
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5937-5950. PubMed ID: 36607429
[TBL] [Abstract] [Full Text] [Related]
5. IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.
Hu Y; Liu D; Cui P; Zhang W; Chen H; Piao C; Lu Y; Liu X; Wang Y; Liu J; Lu X
Invest New Drugs; 2021 Dec; 39(6):1538-1548. PubMed ID: 34387808
[TBL] [Abstract] [Full Text] [Related]
6. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.
Chen H; Jiang T; Lin F; Guan H; Zheng J; Liu Q; Du B; Huang Y; Lin X
Int Immunopharmacol; 2021 Oct; 99():107929. PubMed ID: 34343940
[TBL] [Abstract] [Full Text] [Related]
7. Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects.
Meghnem D; Oldford SA; Haidl ID; Barrett L; Marshall JS
Sci Rep; 2021 Apr; 11(1):9405. PubMed ID: 33931709
[TBL] [Abstract] [Full Text] [Related]
8. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1
Dovedi SJ; Elder MJ; Yang C; Sitnikova SI; Irving L; Hansen A; Hair J; Jones DC; Hasani S; Wang B; Im SA; Tran B; Subramaniam DS; Gainer SD; Vashisht K; Lewis A; Jin X; Kentner S; Mulgrew K; Wang Y; Overstreet MG; Dodgson J; Wu Y; Palazon A; Morrow M; Rainey GJ; Browne GJ; Neal F; Murray TV; Toloczko AD; Dall'Acqua W; Achour I; Freeman DJ; Wilkinson RW; Mazor Y
Cancer Discov; 2021 May; 11(5):1100-1117. PubMed ID: 33419761
[TBL] [Abstract] [Full Text] [Related]
9. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
[TBL] [Abstract] [Full Text] [Related]
10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract] [Full Text] [Related]
11. In vivo antitumour activity of Britanin against gastric cancer through nuclear factor-κB-mediated immune response.
Shi K; Liu X; Du G; Cai X; Zhan Y
J Pharm Pharmacol; 2020 Apr; 72(4):607-618. PubMed ID: 31943207
[TBL] [Abstract] [Full Text] [Related]
12. Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
Qiao G; Wang X; Zhou X; Morse MA; Wu J; Wang S; Song Y; Jiang N; Zhao Y; Zhou L; Zhao J; Di Y; Zhu L; Hobeika A; Ren J; Lyerly HK
Int J Hyperthermia; 2019 Nov; 36(sup1):74-82. PubMed ID: 31795830
[No Abstract] [Full Text] [Related]
13. treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
14. Effects of neoadjuvant chemotherapy combined with enteral nutrition on perioperative immunity, inflammation and intestinal flora in gastric cancer patients.
Zong L; Li H; Li S
J BUON; 2019; 24(3):1113-1119. PubMed ID: 31424669
[TBL] [Abstract] [Full Text] [Related]
15. The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
Eltweri AM; Thomas AL; Chung WY; Morgan B; Thompson J; Dennison AR; Bowrey DJ
Anticancer Res; 2019 Feb; 39(2):853-861. PubMed ID: 30711967
[TBL] [Abstract] [Full Text] [Related]
16. Recombinant Newcastle disease virus (NDV/Anh-il-2) expressing human il-2 as a potential candidate for suppresses growth of hepatoma therapy.
Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W
J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862
[TBL] [Abstract] [Full Text] [Related]
17. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
[TBL] [Abstract] [Full Text] [Related]
18. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
[TBL] [Abstract] [Full Text] [Related]
19. Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells.
Xing R; Li L; Chen L; Gao Z; Wang H; Li W; Cui J; Tian G; Liang Q; Yu J; Sung JJ; Luo G; Gao H; Xu X; Yang H; Wang J; Zhang X; Wang JM; Huang J; Yu Y; Wang J; Lu Y
Oncogene; 2016 May; 35(20):2584-91. PubMed ID: 26364607
[TBL] [Abstract] [Full Text] [Related]
20. Role of Enteral Immunonutrition in Patients Undergoing Surgery for gastric cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Song GM; Tian X; Liang H; Yi LJ; Zhou JG; Zeng Z; Shuai T; Ou YX; Zhang L; Wang Y
Medicine (Baltimore); 2015 Aug; 94(31):e1311. PubMed ID: 26252314
[TBL] [Abstract] [Full Text] [Related]
[Next]
